FOXO4-DRI: research
An experimental cell-clearing peptide with mouse findings and no established human dose.
Also called: FOXO4 DRI, FOXO4-D-retro-inverso, FOX04-DRI, Proxofim.
Senolytic peptides · Experimental FOXO4-p53 interaction-disrupting peptide · Evidence: Animal studies only.
No human dosing study found. Studies of donated human cells or removed tissue are lab work, not human treatment studies.
Studies
- First mouse and cell experiments. animal, Aged, fast-aging and doxorubicin-exposed mice; cultured human fibroblasts.. The peptide cleared some senescent cells and improved selected mouse health measures. (source)
- Testosterone in aged mice. animal, Male mice aged 20-24 months; six mice per treatment group.. Testosterone increased in aged mice; human fertility benefits remain untested. (source)
- Human cartilage cells in a dish. in-vitro, Expanded cartilage cells from human donors, not treated patients.. Fewer senescent cells did not translate into better cartilage formation. (source)
- Radiation and lung scarring in mice. animal, Mouse lung-cancer grafts and radiation-induced lung fibrosis.. Targeting altered fibroblasts improved radiation responses in mouse models. (source)
- Chemically induced lung scarring. animal, Mice given bleomycin to trigger lung scarring.. Three doses reduced lung-scarring measures in this mouse model. (source)
- Pulmonary hypertension harm signal. animal, Pulmonary-hypertension models, including SM22-5-HTT+ mice; human lung samples were examined.. FOXO4-DRI worsened lung-vessel function in one mouse model. (source)
- A second mouse lung-scarring study. animal, Bleomycin-exposed mice and activated fibroblast cultures.. The peptide reduced collagen and tissue changes in a second fibrosis model. (source)
- Lung injury in newborn rats. animal, Newborn rats exposed to 95% oxygen; human autopsy lung samples were examined.. Rat lung structure improved after experimental senescent-cell clearance. (source)
- Sperm production in aged mice. animal, Aged mice, senescent Leydig cells and cocultured germ-cell models.. Sperm quality and sperm production improved in aged mice. (source)
- Human scar tissue in culture. in-vitro, Human keloid fibroblasts and removed keloid tissue grown in culture.. The peptide increased cell death in senescent scar-tissue models. (source)
- How the peptide binds p53. in-vitro, Purified proteins and peptide complexes studied with structural methods.. FOXO4-DRI binds the p53 signaling region directly. (source)
- Blood-vessel aging in mice. animal, Naturally aged mice and D-galactose-exposed mice; cultured human endothelial cells.. Vessel-aging markers improved in mice, with no human dosing data. (source)
- Repeated-dose toxicity in mice. animal, Mouse toxicity comparison of FOXO4-DRI and the distinct peptide CL04183.. Repeated FOXO4-DRI exposure produced liver-toxicity signals in mice. (source)
FOXO4-DRI dosage
Typical reported dose: 3 mg every other day for six doses
- Reported 3 mg on alternate days: 3 mg every other day for six doses every other day for six doses, under the skin. Reported by users, rare report. Studied in: Adult forum self-experimenters; one author describes use with a spouse. (source)
- Reported 40 mg in one day: 5 mg, 5 mg, 10 mg and 20 mg on the same day four injections in one day; no repeat schedule stated, under the skin. Reported by users, rare report. Studied in: One adult LongeCity self-report. (source)
These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.
FOXO4-DRI side effects and risks
Reported side effects
- Injection pain and swelling: Forum reports only; no reliable rate or dose response estimate., moderate. Persistent or worsening pain, redness or swelling needs assessment. (source)
- Low mood or disrupted sleep: One report after a 10 mg total course over three days., moderate. Stop exposure and seek care if symptoms persist or become severe. (source)
- More frequent bowel movements: One person reported this for three days; no clinical rate., mild (source)
- Possible harm to lung circulation: Mouse signal only; human incidence is unknown., serious. New breathlessness, chest pain or fainting needs urgent assessment. (source)
- Possible liver injury: Repeated dose mouse preprint; human incidence is unknown., serious. A clinician may check liver tests after exposure; no validated testing schedule exists. (source)
- Severe allergy or injection-related infection: General unregulated injection risks; no FOXO4 DRI specific rate., serious. Breathing problems need emergency care; hot, painful swelling needs same-day care. (source)
Stop and get help if
- Swollen tongue or throat, trouble breathing, or collapse after an injection.: Stop exposure and call emergency services now.
- Injection site becomes hot, painful or swollen, especially with fever.: Get same-day care. Call emergency services for confusion, fainting or fast breathing.
- New severe breathlessness, chest pain or fainting.: Stop exposure and seek emergency assessment.
Who should avoid it
- pregnant: Precaution: no pregnancy safety data or tested human dose.
- breastfeeding: Precaution: passage into milk and effects on infants are unknown.
- tryingToConceive: Precaution: mouse fertility findings do not establish safety around conception.
- under18: No pediatric dosing or safety study. Newborn-rat experiments do not establish child safety.
- activeCancer: Precaution: it changes p53 signaling. Human cancer-treatment effects are untested; involve the oncology team.
- cancerHistory: Long-term effects on cancer surveillance and recurrence are unknown.
- other: FOXO4-DRI worsened lung-vessel function in a susceptible mouse model; no human safety data.
- heartCondition: Lung-circulation harm in mice makes heart or lung disease a reason for clinician review.
- liverDisease: Repeated-dose liver toxicity appeared in a mouse preprint. No human dose adjustment is known.
- kidneyDisease: Mouse kidney benefits do not establish safety or dose adjustment in kidney disease.
- immunosuppressed: Unregulated injections can cause infection. Risks are higher with a weakened immune system.
- surgeryPlanned: No perioperative safety data. Tell the surgical team about exposure and any injection-site reaction.
- testedAthlete: Falls under the 2026 S0 rule for non-approved drugs; prohibited at all times.
- other: Previous severe allergy to the peptide, diluent or injected product.
Interactions
- Other senolytics: No human combination studies. Adding other cell-killing agents may add toxicity; this is a theoretical concern.
- Cancer therapies: Mouse studies altered responses to chemotherapy or radiation. Human combinations and treatment timing are untested.
- Anticoagulants: General injection-related bleeding concern, especially with muscle injections. No FOXO4-DRI drug interaction has been established.
Product quality risks
- No independent peer-reviewed test-purchase study of online FOXO4-DRI products was found.
- Online injectable peptides may have wrong ingredients, wrong amounts, solvents, particles, microbes or endotoxin.
- Indirect evidence: three online semaglutide samples had 7.7%-14.37% purity and detectable endotoxin. These were not FOXO4-DRI.
- An HPLC purity percentage alone does not prove identity, vial content, sterility or freedom from endotoxin.
How FOXO4-DRI works
Some senescent cells use the proteins FOXO4 and p53 to stay alive. This peptide disrupts their contact and can trigger cell death. That mechanism is supported by lab work; its selectivity in people is unknown.
- FOXO4-p53 interaction: Competes for a p53 binding region involved in senescent-cell survival.
- p53-linked cell-death signals: Can move active p53 out of the nucleus and trigger cell death in susceptible cells.
Half-life: Human half-life is unknown. No human pharmacokinetic study was found.
Gaps: No published human dose-finding, efficacy, safety or pharmacokinetic study found as of 2026-10-18. ClinicalTrials.gov returned zero FOXO4-DRI studies; a FOXO4 keyword hit concerned lymphoma treatment with other drugs. No FDA/EMA label, noncommercial clinician dosing protocol or Cochrane review specific to FOXO4-DRI was found. No studied human maximum exists. aboveStudied is false because true requires a positive studiedMax in this schema; it does not mean any dose is studied. Forum frequency labels describe this small search sample, not population prevalence. Reposts by one author are not independent users. Daily versus alternate-day schedules conflict in one author's reports; several other reports omit the route. No reliable firsthand microdosing titration with a complete route and schedule was verified. No clinical adverse-event rates, reproductive safety, cancer-surveillance outcomes or long-term repeat-course data. Interactions with insulin, sulfonylureas and oral-drug absorption have not been studied. No validated blood marker proves senescent-cell clearance. Normal safety labs cannot establish benefit or safety. CL04183, CL04177, CPP-CAND and FOXO4 gene knockdown are different interventions; their findings cannot supply FOXO4-DRI doses. Han 2022 had a 2024 correction for a misplaced Figure 6B panel; authors state the conclusion is unchanged. The liver-toxicity preprint has inconsistent schedule wording; its numeric FOXO4-DRI dose was not verified here. No FOXO4-specific FDA warning letter or PCAC decision was located. Current nomination status and local possession/import rules remain uncertain. A FOXO4-specific Australian Poisons Standard entry was not confirmed; do not infer Schedule 4 from other peptides.
Related to FOXO4-DRI
- MOTS-c: A peptide the body makes; injection benefits and safety remain unproven.
- Epitalon: A peptide with telomerase effects in cells, but no proof that people live longer.
- Humanin: A peptide the body makes; injection benefits and safety remain unproven.
- Thymalin: A calf thymus extract studied for immune problems, with uncertain safety and product identity.
- Gonadorelin: A short-acting fertility hormone used in tests and specialist pump therapy.
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Cellulitis, NHS · NHS · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Anaphylaxis, NHS · NHS · 2023
- Using intramuscular injections in people on oral anticoagulants, NHS Specialist Pharmacy Service · NHS Specialist Pharmacy Service · 2023
- Access an unapproved therapeutic good (health practitioners), Therapeutic Goods Administration
- Pulmonary hypertension, NHS
- Supply unlicensed medicinal products (specials), MHRA · MHRA
- Unapproved Drugs, FDA
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.